vs
ARBOR REALTY TRUST INC（ABR）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是ARBOR REALTY TRUST INC的1.6倍（$207.3M vs $133.4M），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs -12.1%），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs -8.9%）
Arbor Realty Trust Inc.是总部位于美国的专业房地产投资信托（REIT）企业，主要为多户住宅及商业地产项目提供结构性融资服务，涵盖过渡贷款、机构贷款、夹层融资等品类，服务覆盖美国各地的地产持有者、开发商及房产投资群体。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
ABR vs RARE — 直观对比
营收规模更大
RARE
是对方的1.6倍
$133.4M
营收增速更快
RARE
高出38.0%
-12.1%
两年增速更快
RARE
近两年复合增速
-8.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $133.4M | $207.3M |
| 净利润 | — | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | — | -54.7% |
| 净利率 | — | -62.0% |
| 营收同比 | -12.1% | 25.9% |
| 净利润同比 | — | 3.5% |
| 每股收益（稀释后） | $0.08 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ABRRARE
| Q4 25 | $133.4M | $207.3M | ||
| Q3 25 | $112.4M | $159.9M | ||
| Q2 25 | $130.4M | $166.5M | ||
| Q1 25 | $134.2M | $139.3M | ||
| Q4 24 | $151.7M | $164.6M | ||
| Q3 24 | $156.7M | $139.5M | ||
| Q2 24 | $153.1M | $147.0M | ||
| Q1 24 | $160.7M | $108.8M |
净利润ABRRARE
| Q4 25 | — | $-128.6M | ||
| Q3 25 | $52.0M | $-180.4M | ||
| Q2 25 | $36.3M | $-115.0M | ||
| Q1 25 | $43.4M | $-151.1M | ||
| Q4 24 | — | $-133.2M | ||
| Q3 24 | $73.5M | $-133.5M | ||
| Q2 24 | $61.8M | $-131.6M | ||
| Q1 24 | $73.2M | $-170.7M |
营业利润率ABRRARE
| Q4 25 | — | -54.7% | ||
| Q3 25 | — | -106.9% | ||
| Q2 25 | — | -64.8% | ||
| Q1 25 | — | -102.6% | ||
| Q4 24 | — | -74.3% | ||
| Q3 24 | — | -94.6% | ||
| Q2 24 | — | -79.1% | ||
| Q1 24 | 46.9% | -151.9% |
净利率ABRRARE
| Q4 25 | — | -62.0% | ||
| Q3 25 | 46.3% | -112.8% | ||
| Q2 25 | 27.8% | -69.0% | ||
| Q1 25 | 32.3% | -108.5% | ||
| Q4 24 | — | -80.9% | ||
| Q3 24 | 46.9% | -95.7% | ||
| Q2 24 | 40.4% | -89.5% | ||
| Q1 24 | 45.6% | -156.8% |
每股收益（稀释后）ABRRARE
| Q4 25 | $0.08 | $-1.28 | ||
| Q3 25 | $0.20 | $-1.81 | ||
| Q2 25 | $0.12 | $-1.17 | ||
| Q1 25 | $0.16 | $-1.57 | ||
| Q4 24 | $0.31 | $-1.34 | ||
| Q3 24 | $0.31 | $-1.40 | ||
| Q2 24 | $0.25 | $-1.52 | ||
| Q1 24 | $0.31 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $482.9M | $421.0M |
| 总债务越低越好 | $11.1B | — |
| 股东权益账面价值 | $3.0B | $-80.0M |
| 总资产 | $14.5B | $1.5B |
| 负债/权益比越低杠杆越低 | 3.75× | — |
8季度趋势，按日历期对齐
现金及短期投资ABRRARE
| Q4 25 | $482.9M | $421.0M | ||
| Q3 25 | $423.4M | $202.5M | ||
| Q2 25 | $255.7M | $176.3M | ||
| Q1 25 | $308.8M | $127.1M | ||
| Q4 24 | $503.8M | $174.0M | ||
| Q3 24 | $687.5M | $150.6M | ||
| Q2 24 | $737.5M | $480.7M | ||
| Q1 24 | $908.0M | $112.3M |
总债务ABRRARE
| Q4 25 | $11.1B | — | ||
| Q3 25 | $10.4B | — | ||
| Q2 25 | $10.1B | — | ||
| Q1 25 | $9.9B | — | ||
| Q4 24 | $10.0B | — | ||
| Q3 24 | $10.3B | — | ||
| Q2 24 | $10.6B | — | ||
| Q1 24 | $11.4B | — |
股东权益ABRRARE
| Q4 25 | $3.0B | $-80.0M | ||
| Q3 25 | $3.0B | $9.2M | ||
| Q2 25 | $3.0B | $151.3M | ||
| Q1 25 | $3.0B | $144.2M | ||
| Q4 24 | $3.0B | $255.0M | ||
| Q3 24 | $3.0B | $346.8M | ||
| Q2 24 | $3.1B | $432.4M | ||
| Q1 24 | $3.1B | $140.3M |
总资产ABRRARE
| Q4 25 | $14.5B | $1.5B | ||
| Q3 25 | $13.9B | $1.2B | ||
| Q2 25 | $13.6B | $1.3B | ||
| Q1 25 | $13.4B | $1.3B | ||
| Q4 24 | $13.5B | $1.5B | ||
| Q3 24 | $13.9B | $1.5B | ||
| Q2 24 | $14.2B | $1.6B | ||
| Q1 24 | $15.1B | $1.3B |
负债/权益比ABRRARE
| Q4 25 | 3.75× | — | ||
| Q3 25 | 3.47× | — | ||
| Q2 25 | 3.40× | — | ||
| Q1 25 | 3.29× | — | ||
| Q4 24 | 3.29× | — | ||
| Q3 24 | 3.40× | — | ||
| Q2 24 | 3.47× | — | ||
| Q1 24 | 3.68× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $372.4M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | — | $-100.8M |
| 自由现金流率自由现金流/营收 | — | -48.6% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-472.0M |
8季度趋势，按日历期对齐
经营现金流ABRRARE
| Q4 25 | $372.4M | $-99.8M | ||
| Q3 25 | $178.7M | $-91.4M | ||
| Q2 25 | $60.0M | $-108.3M | ||
| Q1 25 | $150.5M | $-166.5M | ||
| Q4 24 | $461.5M | $-79.3M | ||
| Q3 24 | $85.0M | $-67.0M | ||
| Q2 24 | $69.9M | $-77.0M | ||
| Q1 24 | $260.0M | $-190.7M |
自由现金流ABRRARE
| Q4 25 | — | $-100.8M | ||
| Q3 25 | — | $-92.7M | ||
| Q2 25 | — | $-110.7M | ||
| Q1 25 | — | $-167.8M | ||
| Q4 24 | — | $-79.5M | ||
| Q3 24 | — | $-68.6M | ||
| Q2 24 | — | $-79.0M | ||
| Q1 24 | — | $-193.9M |
自由现金流率ABRRARE
| Q4 25 | — | -48.6% | ||
| Q3 25 | — | -58.0% | ||
| Q2 25 | — | -66.5% | ||
| Q1 25 | — | -120.5% | ||
| Q4 24 | — | -48.3% | ||
| Q3 24 | — | -49.2% | ||
| Q2 24 | — | -53.7% | ||
| Q1 24 | — | -178.2% |
资本支出强度ABRRARE
| Q4 25 | — | 0.5% | ||
| Q3 25 | — | 0.8% | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 1.0% | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | — | 1.2% | ||
| Q2 24 | — | 1.4% | ||
| Q1 24 | — | 3.0% |
现金转化率ABRRARE
| Q4 25 | — | — | ||
| Q3 25 | 3.44× | — | ||
| Q2 25 | 1.65× | — | ||
| Q1 25 | 3.47× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.16× | — | ||
| Q2 24 | 1.13× | — | ||
| Q1 24 | 3.55× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ABR
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
